<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554812</url>
  </required_header>
  <id_info>
    <org_study_id>B9991004</org_study_id>
    <secondary_id>2015-002552-27</secondary_id>
    <secondary_id>JAVELIN MEDLEY</secondary_id>
    <nct_id>NCT02554812</nct_id>
  </id_info>
  <brief_title>A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)</brief_title>
  <official_title>A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics,
      pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination
      with other cancer immunotherapies in patients with locally advanced or metastatic solid
      tumors. The primary purpose is to assess the safety and early signs of efficacy of various
      avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as
      appropriate, in a limited series of indications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK,
      and PD study of avelumab in combination with other immune modulators in adult patients with
      locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC),
      melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer
      (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung
      cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis
      (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of
      care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria
      regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune
      modulators into this study is based on preclinical and clinical data supportive of
      single-agent tolerability and potential clinical benefit, as well as non-clinical data
      suggesting safety, tolerability and clinical benefit of the agent(s) in combination with
      avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as
      follows:

        -  Combination A: avelumab plus utomilumab (4-1BB agonist mAb)

        -  Combination B: avelumab plus PF-04518600 (OX40 agonist mAb)

        -  Combination C: avelumab plus PD 0360324 (M-CSF mAb)

        -  Combination D: avelumab plus utomilumab plus PF-04518600 Each combination will be
           studied individually in 2 study parts: 1) a Phase 1b Lead-in part to evaluate safety,
           and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and
           RP2D (if applicable), of the combination, and 2) a Phase 2 part to evaluate efficacy and
           further evaluate safety of the selected dose from the Phase 1b portion in pre-specified
           patient populations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Anticipated">March 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-Limiting Toxicities (DLT)</measure>
    <time_frame>First 8 weeks of treatment</time_frame>
    <description>For Phase 1b: DLTs for Combination A (avelumab and PF-05082566) or Combination B (avelumab and PF-04518600) or Combination C (avelumab and PD 0360324) or Combination D (Avelumab and utomilumab and PF-04518600)occurring during the first 8 weeks of treatment (first 2 cycles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response - Number of Participants With Objective Response</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>For Phase 2: Number of participants with objective response (ie, confirmed complete or partial response according to RECIST Version 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <description>Cmax defined as the maximum plasma concentration of avelumab (MSB0010718C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-05082566</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, and then on Day 1 of Cycles 3, 5, 8, and 12</time_frame>
    <description>Cmax defined as the maximum plasma concentration of PF-05082566</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <description>Ctrough is defined as the trough plasma concentration at the end of an avelumab dosage interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of PF-05082566</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, and then on Day 1 of Cycles 3, 5, 8, and 12</time_frame>
    <description>Ctrough is defined as the trough plasma concentration at the end of a PF-05082566 dosage interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 10</time_frame>
    <description>Immunogenicity assessment of avelumab (MSB0010718C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of PF-05082566</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 3, 5, 8, and 12</time_frame>
    <description>Immunogenicity assessment of PF-05082566.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Time to Tumor Response (TTR) is defined for patients with confirmed objective response (CR or PR) as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the first documentation of objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Duration of Response (DR) is defined for patients with confirmed objective response (CR or PR) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Progression-Free Survival (PFS) is defined as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Overall Survival (OS) is defined as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor tissue biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Tumor tissue biomarkers, including, but not limited to, PD-L1 expression and tumor infiltrating CD8+ T lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-04518600</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <description>Cmax defined as the maximum plasma concentration of PF-04518600</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of PF-04518600</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 10</time_frame>
    <description>Immunogenicity assessment of PF-04518600.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of PF-04518600</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <description>Ctrough is defined as the trough plasma concentration at the end of a PF-04518600 dosage interval.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + utomilumab (Dose level 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + utomilumab (Dose level 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + utomilumab (Dose level 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melanoma patients treated with avelumab +utomilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCCHN patients treated with avelumab + utomilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNBC patients treated with avelumab + utomilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC first-line Stage IV treated with avelumab +PF-05082566</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04518600 + avelumab in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04518600 + avelumab in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination C Dose escalation cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD 0360324 + avelumab in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination C Dose expansion cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD 0360324 + aveluamb in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination D Dose escalation cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05082566 + PF-04518600 + avelumab in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination D Dose expansion cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05082566 + PF-04518600 + avelumab in selected tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Anti-PD-L1 antibody given until disease progression.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_label>Cohort A6</arm_group_label>
    <arm_group_label>Cohort A7</arm_group_label>
    <arm_group_label>Cohort A8</arm_group_label>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
    <arm_group_label>Combination C Dose escalation cohorts</arm_group_label>
    <arm_group_label>Combination C Dose expansion cohorts</arm_group_label>
    <arm_group_label>Combination D Dose escalation cohorts</arm_group_label>
    <arm_group_label>Combination D Dose expansion cohorts</arm_group_label>
    <arm_group_label>Cohort A9</arm_group_label>
    <arm_group_label>Cohort A10</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utomilumab</intervention_name>
    <description>Anti-4-1BB antibody at 1 of 3 dose levels to optimize the combination with avelumab. Treatment with the combination of avelumab and PF-05082566 will continue until disease progression.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_label>Cohort A6</arm_group_label>
    <arm_group_label>Cohort A7</arm_group_label>
    <arm_group_label>Cohort A8</arm_group_label>
    <arm_group_label>Combination D Dose escalation cohorts</arm_group_label>
    <arm_group_label>Combination D Dose expansion cohorts</arm_group_label>
    <arm_group_label>Cohort A9</arm_group_label>
    <arm_group_label>Cohort A10</arm_group_label>
    <other_name>PF-05082566</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>PF-04518600 will be administered at increasing dose levels in combination with avelumab.</description>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
    <arm_group_label>Combination D Dose escalation cohorts</arm_group_label>
    <arm_group_label>Combination D Dose expansion cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0360324</intervention_name>
    <description>PD 0360324 will be administered at increasing dose levels in combination with avelumab.</description>
    <arm_group_label>Combination C Dose escalation cohorts</arm_group_label>
    <arm_group_label>Combination C Dose expansion cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable
             disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously
             irradiated. Availability of tumor specimen taken within 1 year prior to study entry,
             with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed.
             Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy
             or for which no standard therapy is available, and Phase 2, patients with NSCLC,
             melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC
             must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1
             translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with
             advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard
             therapy or for which no standard therapy is available, and Phase 2, patients with
             NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic
             disease setting allowed. Activating EGFR mutation, ALK, ROS1
             translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN,
             NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior
             therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either
             inoperable or requires extensive resection. Prior treatment with agents targeting
             CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1
             translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN,
             bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements
             are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease
             setting allowed.

          -  ECOG performance status 0 or 1

          -  Estimated life expectancy of at least 3 months

          -  Adequate bone marrow, renal, and liver function

          -  Resolved acute effects of prior therapy

          -  Negative serum pregnancy test at screening

          -  Male and female patients able to have children must agree to use 2 highly effective
             methods of contraception throughout the study and for at least 60 days after last dose

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or
             small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14
             days prior to study entry.

          -  Current or prior use of immunosuppressive medication within 7 days prior to study
             entry

          -  Active autoimmune disease requiring systemic steroids or immunosuppressive agents
             within 7 days prior to study entry

          -  Known prior or suspected hypersensitivity to investigational products

          -  Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry

          -  Patients with known symptomatic brain metastases requiring steroids

          -  Previous high-dose chemotherapy requiring stem cell rescue

          -  Prior allogeneic stem cell transplant or organ graft

          -  Any of the following within 6 months prior to study entry: myocardial infarction,
             uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
             heart failure, cerebrovascular accident, or transient ischemic attack

          -  Symptomatic pulmonary embolism within 6 months prior to study entry

          -  Known HIV or AIDS-related illness

          -  Active infection requiring systemic therapy

          -  Positive HBV or HCV test indicating acute or chronic infection

          -  Administration of a live vaccine within 4 weeks prior to study entry

          -  Diagnosis of other malignancy within 5 years, except for adequately treated basal cell
             or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or
             low-grade (Gleason ≤6) prostate cancer

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study entry and/or during study participation

          -  Persisting toxicity related to prior therapy &gt;Grade 1

          -  Other severe acute or chronic medical condition

          -  Combo C :Existing periorbital edema.

          -  Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture
             (within 12 weeks prior study entry)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center La Jolla (Thornton Hospital)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical Research Unit (Adminstration Office)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Infusion Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IP Shipment: Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center - Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital (BWH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Faber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Pharmacy, Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Investigational Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Breast Center at Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Pharmacy #PH#</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Clinton</city>
        <state>North Carolina</state>
        <zip>28328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPCI Investigational Drug Service</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic &amp; Pharmacy</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford Gynecologic Oncology Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute / Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Health Pharmacy One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Oncology Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Simmons Comprehensive Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse Pharmacy</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Macquarie University Hospital Pharmacy</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MQ Health Cardiology Clinic</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Mater Hospital</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baxter Healthcare</name>
      <address>
        <city>Old Toongabie</city>
        <state>New South Wales</state>
        <zip>2146</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brighton Medical Imaging</name>
      <address>
        <city>Brighton</city>
        <state>Victoria</state>
        <zip>3186</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Victoria</state>
        <zip>3186</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital Malvern</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malvern Medical Imaging</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmacy</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PH 145294, Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Harley Street Clinic</name>
      <address>
        <city>London</city>
        <zip>W1G 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Harley Street Clinic</name>
      <address>
        <city>London</city>
        <zip>W1G 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Japan</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991004&amp;StudyName=A%20Phase%201b%2F2%20Open-label%20Study%20To%20Evaluate%20Safety%2C%20Clinical%20Activity%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Avelumab%2A%20%28msb0010718c%29%20In%20Combination%20With%20Other%20Cancer%20Immunotherapies%20In%20Patients%20With%20Advanced%20Malignancies</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti PD-L1</keyword>
  <keyword>anti 4-1BB</keyword>
  <keyword>OX40 agonist</keyword>
  <keyword>anti M-CSF</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>melanoma</keyword>
  <keyword>squamous cell carcinoma of head and neck (SCCHN)</keyword>
  <keyword>triple negative breast cancer (TNBC)</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>Small cell lung cancer (SCLC)</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>platinum resistant ovarian cancer</keyword>
  <keyword>TGCT/PVNS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

